{"id":548,"date":"2020-09-07T08:01:37","date_gmt":"2020-09-07T08:01:37","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=548"},"modified":"2020-09-07T08:02:40","modified_gmt":"2020-09-07T08:02:40","slug":"discussing-combination-strategies-pre-clinical-and-translational-immune-oncology-developments-at-the-4th-annual-marketsandmarkets-next-gen-immuno-oncology-virtual-congress","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/discussing-combination-strategies-pre-clinical-and-translational-immune-oncology-developments-at-the-4th-annual-marketsandmarkets-next-gen-immuno-oncology-virtual-congress\/","title":{"rendered":"Discussing combination strategies, pre-clinical and translational immune-oncology developments at the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress"},"content":{"rendered":"\n

September 7th<\/sup>\n\u2013 The 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress <\/strong>to\nbe held on 29th\n\u2013 30th October 2020 (British Standard Time)<\/strong> would address the challenges\nand future directions in IO research. The congress aims to bring academicians,\nresearchers and scientists from research institutes pharmaceutical,\nbio-pharmaceutical and biotechnology companies to discuss the latest updates in\ndevelopment of ADC\u2019s, Bispecific Antibodies, Cellular Therapy and Immune\nCheckpoint Inhibitors. <\/p>\n\n\n\n

4th Annual MarketsandMarkets\nNext Gen Immuno-Oncology Virtual Congress<\/strong> will\ngather 20+ sponsors, 30+ leading industry speakers and 200+ professional. The\n2-day event will focus on various combination strategies, pre-clinical and\ntranslational immune-oncology developments, updates in cellular and viral\ntherapies, vaccines development and personalized immunotherapy. Keynote\npresentations, Brainstorming Panel Discussions and Case studies will give the\nstakeholders an opportunity to discuss and understand the issues faced and come\nup with solutions.<\/p>\n\n\n\n

Stefan Glueck<\/strong>, Vice <\/strong>President, Global\nHead Franchise Oncology, Regeneron, USA <\/strong>will be presenting a keynote\non \u2018ICI and chemotherapy, why and how\u2019 <\/strong>which\nwill further deep dive into how Combining chemotherapy with ICI Increases\nefficacy, Seems to reduce some irSAEs and how it is now standard of care in\nmany solid tumors.<\/p>\n\n\n\n

Eugene Zhukovsky, <\/strong>Chief Scientific Officer, Biomunex Pharmaceuticals, France <\/strong>will be speaking about \u2018A versatile Plug-and-Play platform, BiXAb, for development of bispecific antibodies with a diverse set of mechanisms of action\u2019.<\/strong> The Presentation will cover topics about how Tetra-Fab BiXAb\u00ae possesses excellent drug-like properties, how the Platform is ideal for leveraging diverse MOAs and present examples which will include the targeting of solid tumors and hematological malignancies.<\/p>\n\n\n\n

Fabienne Hermitte, <\/strong>President, Medical Affairs, HalioDx <\/strong>will talk about \u201cBiomarkers for prognosis and prediction to\nimmunotherapies<\/strong>\u201d. The presentation will further deep dive into  Why gaining insights in the immune contexture\nof tumors is crucial for predicting response and resistance to immunotherapies, How biomarker evaluation can impact\nimmunotherapy drug development and What are the benefits of using Immunogram\nand Immunoscore\u00ae platforms in your translational research studies.<\/p>\n\n\n\n

Over the two days, the event will\nalso host expert speakers from Merck Sharp & Dohme, Immunocore, Cancer Research\nUK Barts Centre, APO-T, Celyad, Pieris Pharmaceuticals, King\u2019s College London, 4D\nPharma Research, Elstar Therapeutics, ImCheck Therapeutics, University of\nSouthampton, Transcure Bioservices, Promocell, University of Nottingham, etc.<\/p>\n\n\n\n

Companies like Proteome Science, Ultivue,\nMiltenyi Biotech, Imaging Endpoints, Thermofisher Scientific, GenScript,\nPersonalis, Promocell, Transcure Bioservcies, MiMabs, MBL International, HalioDx,\nKDBIO, Synthace, Aquila Biomedical, Horizonn, Marks&Clerk<\/strong> are all set to showcase\ntheir product, solutions and services at this Mabdesgn and One Nucleus supported\nConference. The event has also been endorsed by leading partners like Pharma\nJournalist, Medical Events Guide, PharmaTutor, Mednous, Technology Networks and\nGen Engineering.<\/p>\n\n\n\n

\"\"
https:\/\/events.marketsandmarkets.com\/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress\/<\/a><\/figcaption><\/figure>\n\n\n\n

The event overview, registration\ndetails and complete speaker list are available on the official website. You\ncan also download the complete agenda to identify the potential interest in the\nconference on this page \u2013 https:\/\/bit.ly\/35eHcXg<\/a> oryou can directly email onevents@marketsandmarkets.com<\/a> <\/strong>asking for more details, your queries and provide feedback.<\/p>\n\n\n\n

Markets and Markets Conferences (MnM\nConferences) produces global summits, congresses and conferences bringing\ntogether key industry experts from academia and industry, fostering the\nexchange of ideas and latest research through cutting edge conference programs,\ninteractive panel and round table discussions. Conferences are currently held\nor planned in the UK, Europe, USA and across Asia.<\/p>\n\n\n\n

Contact Person \u2013 Shardul Oza<\/p>\n\n\n\n

Email: shardul.oza@marketsandmarkets.com<\/p>\n\n\n\n

Contact Number – +91 8390683057<\/p>\n","protected":false},"excerpt":{"rendered":"

September 7th \u2013 The 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 29th \u2013 30th October 2020 (British Standard Time) would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest […]<\/p>\n","protected":false},"author":2,"featured_media":552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,5,2],"tags":[228,229,230,226,225,227],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/548"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=548"}],"version-history":[{"count":2,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/548\/revisions"}],"predecessor-version":[{"id":553,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/548\/revisions\/553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/552"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}